Explore

Rapid Read Rapid Read
Recursion's Efforts in Rare Disease Research Highlighted by Patient Advocate's Story

Recursion's Efforts in Rare Disease Research Highlighted by Patient Advocate's Story

Recursion, a techbio company based in Salt Lake City, recently hosted an event where Jenny Jones, a patient advocate, shared her family's history with familial adenomatous polyposis (FAP), a rare genetic disease. FAP causes noncancerous polyps to develop in the colon and rectum, which can turn cancerous if untreated. Jenny's family has a long history with FAP, tracing back to her great grandparents. Her mother, diagnosed with colorectal cancer at 34, underwent multiple surgeries and eventually succumbed to the disease. Jenny herself was diagnosed at 8 and has undergone several surgeries, including the removal of her colon. Despite these challenges, she founded 'Life’s a Polyp' to raise awareness about FAP. Recursion is currently testing a treatment, REC-4881, which aims to reduce polyp burden in FAP patients.
Trendline Trendline
Altitude Labs Empowers Biotech Founders with Education and Investment Opportunities

Altitude Labs Empowers Biotech Founders with Education and Investment Opportunities

Altitude Labs Empowers Biotech Founders with Education and Investment Opportunities
Trendline Trendline
Veradermics Announces Successful Late-Stage Trial for Hair Loss Drug VDPHL01

Veradermics Announces Successful Late-Stage Trial for Hair Loss Drug VDPHL01

Veradermics Announces Successful Late-Stage Trial for Hair Loss Drug VDPHL01
Trendline Trendline
Novo Nordisk's Stock Rises Amid Weak Eli Lilly Drug Uptake and Positive Clinical Trials

Novo Nordisk's Stock Rises Amid Weak Eli Lilly Drug Uptake and Positive Clinical Trials

Novo Nordisk's Stock Rises Amid Weak Eli Lilly Drug Uptake and Positive Clinical Trials
Trendline Trendline
Emergent BioSolutions Partners with SAB Biotherapeutics for Type 1 Diabetes Treatment

Emergent BioSolutions Partners with SAB Biotherapeutics for Type 1 Diabetes Treatment

Emergent BioSolutions Partners with SAB Biotherapeutics for Type 1 Diabetes Treatment
Trendline Trendline
FDA Initiates AI-Driven Pilot to Accelerate Clinical Trials

FDA Initiates AI-Driven Pilot to Accelerate Clinical Trials

FDA Initiates AI-Driven Pilot to Accelerate Clinical Trials
Trendline Trendline
Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility
Rapid Read Rapid Read
Paradigm Health and FDA Collaborate to Enhance Clinical Trial Review Process

Paradigm Health and FDA Collaborate to Enhance Clinical Trial Review Process

Paradigm Health has announced a collaboration with the U.S. Food & Drug Administration (FDA) to develop a new model for accelerating clinical trial execution and regulatory review. This initiative utilizes Paradigm Health's technology-enabled Study Conduct platform, which automates data collection and analysis, allowing for real-time review by the FDA. The collaboration aims to reduce the burden of monitoring, data entry, and trial costs, thereby speeding up regulatory review and improving the efficiency of U.S. clinical trials. The model is currently being tested in a Phase 2 trial sponsored by AstraZeneca and a Phase 1b trial sponsored by Amgen. The platform captures data from electronic health records and other sources, evaluates it algorithmically, and transmits only critical signals to the FDA and trial sponsors.
Trendline Trendline
Emergent BioSolutions Secures $50M Deal with SAB Biotherapeutics for Diabetes Treatment

Emergent BioSolutions Secures $50M Deal with SAB Biotherapeutics for Diabetes Treatment

Emergent BioSolutions Secures $50M Deal with SAB Biotherapeutics for Diabetes Treatment
Trendline Trendline
Veradermics' Hair Loss Drug Shows Promising Results in Late-Stage Trial

Veradermics' Hair Loss Drug Shows Promising Results in Late-Stage Trial

Veradermics' Hair Loss Drug Shows Promising Results in Late-Stage Trial
Trendline Trendline
Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment

Veradermics Announces Conference Call to Discuss Phase 2/3 Study Results for Hair Loss Treatment
Rapid Read Rapid Read
FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Treatment

FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Treatment

AstraZeneca's Saphnelo (anifrolumab) has received approval from the U.S. Food and Drug Administration (FDA) for self-administration as a once-weekly autoinjector, known as the Saphnelo Pen, for adults with systemic lupus erythematosus (SLE). This decision follows the successful Phase III TULIP-SC trial, which showed that subcutaneous administration of Saphnelo significantly reduced disease activity in patients with moderate to severe SLE. The trial's findings, published in Arthritis & Rheumatology, confirmed the safety and efficacy of the autoinjector, aligning with the known profile of Saphnelo when given intravenously. This approval is expected to enhance treatment accessibility and convenience for lupus patients.